PATENT ABSTRACTS 515

an afflicted host pharmaceutical compositions containing a therapeutically effective amount of urine peptide fractions containing 3-(N-phenyl acetyla minopiperidine)-2,6-dion. The therapeutically effective urine pept ide fractions of this invention, termed Antineoplastons A2 and A5, are obtaine d by two separate processes: Antineoplaston A2 is prepared by providing a volu me of urine; separating from the urine par- ticulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating fro m the acidified urine any precipitated matter; introducing the acidified urine to a first chromatography column con- taining a polymeric resin adsorbent; elut ing the column to recover an eluate; adjusting the pH of the eluate to between about 2 and 8; introducing the adjusted eluate to a second chromatography col umn; and recovering the peptide fraction containing the compound 3-(N-phenyl ac etyla minopiperidine(-2,6-dion. Antineoplaston A5 is prepared by providing a v olume of urine; separating from the urine particulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating from the acidified urine any precipitated matter; in- troducing the acidified ur ine to a chromatography column; eluting the column with a lower alkyl alcohol having from 1 to 8 car- bon atoms; and recovering the peptide fraction containing the compound 3-(N-phenyl acetyla minopiperidine)-2,6-dion.

PS wherein RI and R2 are amino acid residues selected from Ala, Asn, Arg, GIy, Leu, Pro, Ser, and Thr with the provision that RI and R2 are not both Gly; and See Patent for Tabular Pre- sentation PS The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for as- saying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma. In an assay for determining the state of Epstein- Barr virus infection, the synthetic potypeptide is fixed to first and second solid phases supports which can be provided by a double-welled spoon having two adjacent solid phases. The solids phases are each coated with the synthetic poly- peptide. After contacting each solid phase with a body sample, one is contacted with anti-human IgG antibodies having a linked indicating means and the other is contacted with anti-human lgM antibodies having a linked indicating means. Each solid phase is contacted with a color- forming reactant, and by comparing color in- tensity resulting from each solid phase, the state of infection is determined.

5116731

P R O C E S S F O R T H E D E T E C T I O N O F A N A L L E R G Y O R A N A N T I -

A L L E R G I C S U B S T A N C E

5116725

A S S A Y F O R E P S T E I N - B A R R V I R U S I N F E C T I O N W I T H S O L I D

P H A S E B O U N D S Y N T H E T I C P O L Y P E P T I D E S

John H Vaughan, Dennis A Carson, Gary Rhodes, Richard Houghten, Richard S Smith, John E Geltosky assigned to Scripps Clinic and Research Foundation

Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to ab- out 40 amino acid residues that includes the overlapping five and six amino acid residue sequences See Patent for Tabular Presentation

Otto-Henning Wilhelms, Weinheim Ritten- weier, Federal Republic Of Germany assigned to Boehringer Mannheim GmbH

The present invention provides a one-step pro- cess for the detection of the presence of an allergy and for the specific detection of the allergen responsible for the allergy, in which the leukocytes of a sample to be investigated are in- cubated with an allergen or with another stimulation factor in an aqueous medium together with a chromogenic protease substrate and calcium ions, the liberated protease is reac- ted with the chromogen and the resulting chromophor is determined. The protease activity is measured kinetically after an incubation period by the increase of the chromophor con- centration. The present invention also provides a reagent and a device for carrying out this pro- cess, as well as a process for the determination of antiallergic and anti-inflammatory substances. The device consists of a microtiter plate with a plurality of different reagents arranged in rows.